Analytical performance of the serum free light chain assay

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 1, 2010, Pages 73-79

  Briand, Pierre Yves ^a   Decaux, Olivier ^b   Caillon, Hélène ^a   Grosbois, Bernard ^b   Le Treut, André ^a   Guenet, Lucienne ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Free light chains; Immunoassay; Monoclonal gammopathy

Indexed keywords

ACCURACY; ARTICLE; CONTROLLED STUDY; DILUTION; FREE LIGHT CHAIN ASSAY; HUMAN; IMMUNOASSAY; LIGHT CHAIN; NEPHELOMETRY; PERFORMANCE; PRIORITY JOURNAL; REPRODUCIBILITY;

HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; NEPHELOMETRY AND TURBIDIMETRY; PARAPROTEINEMIAS; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 74549176580     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.012     Document Type: Article

References (20)

1. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473
2. Guidelines Working Group of UK Myeloma Forum. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004;125:681-700.
3. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004;126:348-354
4. Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, DeGoey R, et al. Appraisal of immmunoglobulin free light chain as a marker of response. Blood 2008;111:4908-4915
5. Rajkumar SV, Kyle RA, Therneau TM, Melton III LJ, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106:812-817
6. Katzmann JA, Dispenzieri A, Kyle R, Snyder MR, Plevak BS, Larson DR, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006;81:1575-1578
7. Guenet L, Decaux O, Lechartier H, Ropert M, Grosbois B. Intérêt du dosage des chaînes légères libres d'immunoglobulines sériques pour le diagnostic et le suivi des gammapathies monoclonales. Rev Med Int 2007;28:689-697
8. Freelite human kappa free kit for use on the Dade Behring Nephelometer (BN™II). LK016.T. The Binding Site Ltd., 2008.
9. Freelite human lambda free kit for use on the Dade Behring Nephelometer (BN™II). LK018.T. The Binding Site Ltd., 2008.
10. Tate J, Mollee P, Dimeski G, Carter A, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 2007;376:30-36
11. Tillyer CR, Iqbal J, Raymond J, Gore M, McIlwain TJ. Immunoturbidimetric assay for estimating free light chains of immunoglobulins in urine and serum. J Clin Pathol 1991;44:466-471
12. Tate J, Gill D, Cobcroft R, Hickman PE. Practical considerations for the measurement of free light chains in serum. Clin Chem 2003;49:1252-1257 (Pubitemid 36900609)
13. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-680
14. Abraham RS, Charlesworth MC, Owen BA, Benson LM, Katzmann JA, Reeder CB. Trimolecular complexes of l light chains dimers in serum of a patient with multiple myeloma. Clin Chem 2002;48:1805-1811
15. Lopez J, Dauwalder O, Joly P, Dimet I, Bienvenu J, Bernon H. Intérêts et limites des dosages sériques et urinaires des chaînes légères libres pour le diagnostic et le suivi des dysglobuliné- mies monoclonales. Ann Biol Clin 2006;64:287-297
16. Mead GP, Stubbs PS, Carr-Smith HD, Drew RL, Bradwell AR. Nephelometric measurement of serum free light chains in nonsecretory myeloma [abstract]. Clin Chem 2002;48(Suppl 6):A23.
17. Chapuis-Cellier C, Chazaud A, Foray V, Troncy J. Apparent discrepencies in the quantification of free light chains in serum of patients presenting with a monoclonal gammmopathy. Haematologica 2005;90:109.
18. Pattenden RJ, Rogers SY, Wenham PR. Serum free light chains; the need to establish local reference intervals. Ann Clin Biochem 2007;44:512-515
19. Nakano T, Miyazaki S, Takahashi H, Matsumori A, Maruyama T, Komoda T, et al. Immunochemical quantification of free immunoglobulin light chains from an analytical perspective. Clin Chem Lab Med 2006;44:522-532
20. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005; 79:319-328